我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

卡维地洛对慢性充血性心力衰竭患者脑钠尿肽(BNP)浓度及预后的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2007年第6期
页码:
661-662/666
栏目:
临床研究
出版日期:
2007-12-20

文章信息/Info

Title:
Influence of Carvedilol on treatment and prognosis in patients with chronic heart failure
作者:
蔡建华; 宋丹; 彭剑; 汪敏
武汉亚洲心脏病医院,湖北 武汉 430022
Author(s):
CAI Jian-hua;  SONG Dan;  PENG Jian;  WANG Min
Department of Cardiology, Wuhan Asian Heart Hospital, WuHan 430022, Hubei, China
关键词:
心力衰竭; 卡维地洛; 脑钠尿肽; 预后
Keywords:
Chronic heart failure; Carvedilol; B-type natriuretic; Prognosis
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
目的 观察卡维地洛对慢性充血性心衰（CHF）患者脑钠尿肽(BNP)浓度影响及心衰预后的关系。方法 70例CHF患者随机分为常规治疗组(34例)和卡维地洛组（常规治疗基础上加用卡维地洛,36例)。测定两组患者治疗前、治疗2周后BNP 浓度及心功能,观察卡维地洛对心功能、BNP浓度的影响;以12个月内因心衰再入院或死亡作为观察终点,评价卡维地洛对心衰长期预后的影响。结果 治疗后卡维地洛组与常规治疗组均有临床心功能级别、BNP浓度下降(P<0.05),卡维地洛组BNP浓度下降更显著(P<0.05) ;卡维地洛组6例发生终点事件其发生率16.6%,高于常规治疗组17例发生终点事件(发生率50%，P<0.01) ;所有终点事件发生病例的BNP＞700 μg/L(治疗2周后)。结论 卡维地洛可以改善心衰患者预后；BNP＞700 μg/L(治疗2周后)提示预后不良。
Abstract:
AIM To observe the effects of Carvedilol on changes of Btype natriuretic peptide (BNP) concentration in chronic heart failure patients and their relation with the prognosis of these patients. METHODS We followed 70 patients with chronic heart failure, measuring pre and post treatment BNP concentration. The subjects were divided into two groups based on with or without Carvedilol. The Carvedilol group consisted of 36 cases and the nonCarvedilol group were made up of 34 cases. Endpoints were death or 12 month readmission. RESULTS The BNP levels decreased more markedly in Cardevilol group (P<0.05). There were 6 endpoint events in Carvedilol group (16.6%) and 17 endpoint events in nonCarvedilol group (50%), with significant difference between the two groups ( P< 0.01). CONCLUSION Carvedilol decreases the BNP level and improves the prognosis in patients with chronic heart failure; post treatment BNP levels can be used to predict the prognosis.

参考文献/References

［1］ Maisel AS, Koon J, Krishnaswamy P, et al. Utility of Bnatriuretic peptide as a rapid, pointofcare test for screening patients undergoing echocardiography to determine left ventricular dysfunction［J］. Am Heart J,2001,141（3）:367-374.

［2］ Herman RB, Jesudason PJ, Mustafa AM, et al. Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans［J］ . Br J Clin Pharmacol, 2003,55 (2) : 134-138.

［3］ Lechat P, Packer M, Chalon S,et al. Clinical effects of beta adrenergic blockade in chronic heart failure : a meta analysis of double blind, placebocontrolled, randomized trials ［J］ . Circulation,1998,98 (12) : 1184-1191.

［4］ Bristow MR. Betaadrenergic receptor blockade in chronic heartfailure［J］ . Circulation, 2000,101(5) : 558-569.

［5］ Sanderson J E, Chan SK, Yip G, et al. Beta2blockade in heart failure : a comparison of carvedilol with metoprolol［J］ . J Am Coll Cardiol, 1999, 34 (5) : 1522-1528.

［6］ Rossig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis : protective role of carvedilol ［J］ . J Am Coll Cardiol, 2000,36(7) : 2081-2089.

［7］ Packer M, Fowler MB, Roecker EB,et al.Effect of carvedilol on the morbidity of patients with severe chronic heart failure : results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study［J］. Circulation, 2002,106(17) :2194-2199.

［8］ Fowler MB, VeraLlonch M, Oster G, et al. Influence of carvedilol on hospitalizations in heart failure : incidence, resource utilization and costs. U. S. Carvedilol Heart Failure Study Group［J］. J Am Coll Cardiol, 2001, 37（6） :1692-1699.

备注/Memo

备注/Memo:
收稿日期：2006-06-09.作者简介：蔡建华，副主任医师，硕士 Email：Ccaijianhua@yahoo.com.cn
更新日期/Last Update: